title: ALK inhibitor.
authors.affiliation: sakamotohrs@chugai-pharm.co.jp
authors.forename: Hiroshi
authors.initials: H
authors.lastname: Sakamoto
mesh_terms: D000077548:Anaplastic Lymphoma Kinase; D002986:Clinical Trials as Topic; D000077547:Crizotinib; D055808:Drug Discovery; D006801:Humans; D008175:Lung Neoplasms / Q000235:genetics; D058990:Molecular Targeted Therapy; D047428:Protein Kinase Inhibitors / Q000494:pharmacology* / Q000627:therapeutic use*; D011720:Pyrazoles / Q000494:pharmacology* / Q000627:therapeutic use*; D011725:Pyridines / Q000494:pharmacology* / Q000627:therapeutic use*; D020794:Receptor Protein-Tyrosine Kinases / Q000037:antagonists & inhibitors* / Q000235:genetics* / Q000502:physiology; D055752:Small Cell Lung Carcinoma / Q000235:genetics
chemical_list: D047428:Protein Kinase Inhibitors; D011720:Pyrazoles; D011725:Pyridines; D000077547:Crizotinib; C000626173:ALK protein, human; D000077548:Anaplastic Lymphoma Kinase; D020794:Receptor Protein-Tyrosine Kinases